Primaa raises €7M to accelerate product growth and international expansion

October 29, 2025 at 06:00 AM UTC
Tech.eu
Original: EN
Primaa raises €7M to accelerate product growth and international expansion

Paris-based Primaa, a developer of AI software for cancer diagnostics, has secured €7 million in extended funding. This investment round, backed by MH Innov’, Elaia, and SWEN Capital Partners, signals growing confidence in AI-driven solutions within the European healthcare sector and its potential to enhance diagnostic capabilities. Primaa's AI tools, including Cleo Breast (CE-IVDR) and Cleo Skin, automate the detection and quantification of cancer biomarkers. Cleo Breast aids in breast cancer diagnostics, while Cleo Skin, currently undergoing CE marking, is designed for melanoma, squamous cell carcinoma, and basal cell carcinoma detection on histological slides. These solutions are already deployed in leading French medical institutions like Institut Curie and are expanding across Europe. This funding will bolster Primaa's sales organization to accelerate European deployment and improve customer support. Furthermore, it will drive the development of new features, including predictive AI models for disease progression, and support international expansion, particularly in the United States, with plans for FDA certification. These advancements promise to improve diagnostic accuracy and ease the workload of pathologists across Europe. Primaa's ongoing development of solutions for cervical and prostate cancer further highlights its commitment to advancing AI-powered diagnostic tools within the European healthcare landscape. This expansion reflects the broader trend of leveraging technology to improve patient care and diagnostic efficiency.

To provide multilingual access, this article summary was automatically generated.

Source Information

Publication: Tech.eu
Published: October 29, 2025 at 06:00 AM UTC
All rights remain with the original publisher.